Pfizer (NYSE:PFE) Shares Down 0.8%

Pfizer Inc. (NYSE:PFE) shares fell 0.8% on Thursday . The stock traded as low as $27.07 and last traded at $27.21. 6,980,756 shares were traded during trading, a decline of 83% from the average session volume of 40,797,551 shares. The stock had previously closed at $27.42.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PFE shares. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Morgan Stanley raised their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Trading Up 0.7 %

The business’s 50-day simple moving average is $27.81 and its 200-day simple moving average is $27.69. The company has a market cap of $156.45 billion, a PE ratio of -458.26, a P/E/G ratio of 1.10 and a beta of 0.70. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period last year, the company earned $1.23 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.08%. Pfizer’s dividend payout ratio is -2,799.53%.

Institutional Trading of Pfizer

Several large investors have recently added to or reduced their stakes in PFE. GoalVest Advisory LLC boosted its holdings in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Creekmur Asset Management LLC acquired a new position in shares of Pfizer during the 4th quarter valued at about $32,000. Trivant Custom Portfolio Group LLC raised its stake in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares in the last quarter. VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the fourth quarter worth approximately $36,000. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.